34
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Effect of Lipid Dose on the Redistribution and Blood Pool Clearance Kinetics of Peg-Modified Technetium-Labeled Lipid Vesicles

&
Pages 381-390 | Published online: 28 Sep 2008

References

  • Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carrier Syst 1987; 3: 123–193
  • Phillips W.T., Rudolph A.S., Goins B., Klipper R. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studies with newly developed 99m-technetium liposome label. Biomaterials, Artificial Cells and Immobilization Technology 1992; 20: 757–760
  • Storm G., Oussoren C., Peeters P.A.M., Barenholz Y. Tolerability of liposomes in vivo. Liposome Technology, Volume III, G. Gregoriadis. CRC Press, BocaRaton, FL 1993; 345–83
  • Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991; 1068: 133–141
  • Woodle M.C., LasiC D.D. Sterically-stabilized liposomes. Biochim Biophys Acta 1992; 113: 171–199
  • Papahajopoulos D., Allen T., Gabizon A., Mayhew E., Matthay K., Huang S.K., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: significant improvements in blood clearance, tissue deposition and therapeutic index of encapsulated drugs against implanted tumors. Proc Natl Acad Sci USA 1991; 88: 1460–11464
  • Woodle M.C. 67-Gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. J Nucl Med Biol 1993; 20: 149–155
  • Tilcock C., Yap M., Szucs M., Utkhede D. PEG-modified lipid vesicles with encapsulated technetium-99m as blood pool agents for nuclear medicine. J Nucl Med 1994; 21: 165–170
  • Goins B., Phillips W.T., Klipper R. Blood-pool imaging using technetium-99m-labeled liposomes. J Nucl Med 1996; 37: 1374–1379
  • Phillips W.T., Rudolph A.S., Goins B., Timmons J.H., Klipper R., Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. J Nucl Med 1992; 19: 539–547
  • Tilcock C., Ahkong Q.F., Fisher D. 99mTc-labeling of lipid vesicles containing the lipophilic chelator PE-Dtta: effect of tin-to-chelate ratio, chelate content and surface polymer on labeling efficiency and biodistribution behavior. Nucl Med Biol 1994; 21: 89–96
  • Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066: 29–36
  • Litzinger D.C., Huang L. Ampipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in the spleen. Biochim Biophys Acta 1992; 112: 249–254
  • Allen T.M., Papahadjopoulos D. Sterically stabilized (stealth) liposomes: Pharmacokinetics and therapeutic advantages in Liposome Technology, Volume III, 2nd edition, G. Gregoriadis. CRC Press, Boca Raton, FL 1992; 59–72
  • Zalipsky S., Hansen C.B., Oaks J.M., Allen T. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci 1996; 85: 133–137
  • Torchilin V.P., Trubetskoy V.S., Whiteman K.R., Caliceti P., Ferruti P., Veronese F.M. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci 1995; 84: 1049–1053
  • Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer coated longevity. Biochim Biophys Acta 1994; 1195: 11–20
  • Needham D., McIntosh T.J., Lasic D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992; 1108: 40–48
  • Blume G., Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1993; 1146: 157–168
  • Liu D., Song Y.K., Liu F. Antibody dependent, complement mediated liver uptake of liposomes containing GM1. J Pharm Res 1995; 12: 1775–1780
  • Harashima H., Sakata K., Funato K., Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. J Pharm Res 1994; 11: 402–406
  • Liu D., Liu F., Song Y.K. Recognition and clearance of liposomes containing phospatidylserine are mediated by serum opsonins. Biochim Biophys Acta 1995; 140–146
  • Liu F., Liu D. Serum independent liposome uptake by mouse liver. Biochim Biophys Acta 1996; 1278: 5–11
  • Liu D., Hu Q., Song Y.K. Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta. 1995; 1240: 277–284
  • Marjan J., Xie Z., Devine D. Liposome-induced activation of the classical complement pathway does not require immunoglobins. Biochim Biophys Acta 1994; 1192: 35–44
  • Oja C.D., Semple S.C., Chonn A., Cullis P.R. Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta 1996; 1281: 31–37
  • Harashima H., Sakata K., Kiwada H. Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes. J Pharm Res 1993; 10: 606–610
  • Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994; 1191: 43–51
  • Allen T.M., Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989; 981: 27–35
  • Chilton H.M., Brown M.L. Radiopharmaceuticals for abdominal and gastrointestinal imaging: reticuloendothelial, hepatobiliary, and intestinal in Pharmaceuticals in Medical Imaging, D.P Swanson, H.M Chilton, J.H. Thrall. Macmillan Publishing Co., Inc., New York 1990; 462–500
  • Adalet I., Cantez S. Poor-quality red blood cell labeling with technetium-99m: case report and review of the literature. Eur J Nucl Med 1994; 212: 173–175
  • Hambye A.S., Vandermeiren R., Vervaet A., Vandevivere J. Failure to label red blood cells adequately in daily practice using an in vivo method: methodological and clinical considerations. Eur J Nucl Med. 1995; 22: 61–76

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.